The combination of curcumin and 5-fluorouracil in cancer therapy

Arch Pharm Res. 2018 Jan;41(1):1-13. doi: 10.1007/s12272-017-0979-x. Epub 2017 Dec 11.

Abstract

5-Fluorouracil (5-FU) alone or in combination with other therapeutic drugs has been widely used for clinical treatment of various cancers. However, 5-FU-based chemotherapy has limited anticancer efficacy in clinic due to multidrug resistance and dose-limiting cytotoxicity. Some molecules and genes in cancer cells, such as nuclear factor kappa B, insulin-like growth factor-1 receptor, epidermal growth factor receptor, cyclooxygenase-2, signal transducer and activator of transcription 3, phosphatase and tensin homolog deleted on chromosome ten and Bcl-2 etc. are related to the chemoresistance and sensitivity of cancer cells to 5-FU. The activation of these molecules and genes expressions in cancer cells will be increased or decreased with long-term exposure of 5-FU. Curcumin has been found to be able to negatively regulate these processes. In order to overcome the problems of 5-FU, curcumin has been used to combine with 5-FU in cancer therapy.

Keywords: 5-Fluorouracil (5-FU); Anticancer efficacy; Combination therapy; Curcumin; Cytotoxicity; Multidrug resistance (MDR).

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • Curcumin / chemistry
  • Curcumin / pharmacology*
  • Fluorouracil / chemistry
  • Fluorouracil / pharmacology*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Curcumin
  • Fluorouracil